Research Landing

Heart rhythm

CABANA Trial
Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation

Inclusion criteria

  • Have documented AF episodes >two episodes over four months with electrocardiographic documentation of  one episode or at least one episode of AF lasting more than one week
  • Warrant active therapy beyond simple ongoing observation
  • Be eligible for catheter ablation and >two sequential rhythm control and/or >three rate control drugs
  • Be >65 years of age, or <65 years with one or more of the following risk factors for stroke: 
    • Hypertension
    • Diabetes
    • Congestive heart failure (including systolic or diastolic heart failure)
    • Prior stroke or TIA
    • LA size >5.0cm (or volume index >44cc/m2) or EF<35
    • Subjects <65 years of age whose only risk factor is hypertension must have a second risk factor or LV hypertrophy to qualify 

Exclusion criteria

  • Lone AF in absence of risk factors for stroke in patients <65 years of age
  • Patients who in the opinion of managing clinician should not yet receive any therapy for AF
  • Patients who have failed >two membrane active anti-arrhythmic drugs at a therapeutic dose due to inefficacy or side effects
  • More than one week of amiodarone treatment in the past three months
  • An efficacy failure of full-dose amiodarone treatment >12 weeks duration at any time

Principal investigator: Blair Halperin, M.D.
Sponsor: National Heart Lung and Blood Institute (NHLBI)
Contact: Heather Aiona, CCRC, clinical research coordinator, 503-216-2099

ST. JUDE QUICK FLEX Registry
QuickFlex® Model 1258T Left Heart Pacing Lead Post Approval Study: CRT-D (Cardiac Resynchronization Therapy Defibrillator)

Sponsor: St. Jude Medical
Principal investigator: Alexi Zemsky, M.D.
Contact: Jan Coan, CCRC, study coordinator, 503-963-3026